Id: | acc2112 |
Group: | 2sens |
Protein: | STAT3 |
Gene Symbol: | STAT3 |
Protein Id: | P40763 |
Protein Name: | STAT3_HUMAN |
PTM: | phosphorylation |
Site: | Ser727 |
Site Sequence: | CSNTIDLPMSPRTLDSLMQFG |
Disease Category: | Cancer |
Disease: | Lung Cancer |
Disease Subtype: | LUAD |
Disease Cellline: | A549 |
Disease Info: | |
Drug: | Cisplatin |
Drug Info: | "Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various malignancies, including ovarian, bladder, testicular, and non-small cell lung cancers, by forming DNA cross-links to interfere with replication and repair, thereby inhibiting cancer cell growth and proliferation." |
Effect: | resist |
Effect Info: | Inhibiting the phosphorylation of Ser727 site of STAT3 with rapamycin can sensitize cells to cisplatin. |
Note: | |
Score: | 5.0 |
Pubmed(PMID): | 34543857 |
Sentence Index: | 34543857_4-5 |
Sentence: | "It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. In this study, using a proteomic approach, we revealed important targets and signaling pathways altered in cisplatin-resistant A549 lung adenocarcinoma cells." |
Sequence & Structure:
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 2 | Recruiting | head and neck squamous cell carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 2 | Active, not recruiting | non-small cell lung carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 2 | Completed | non-small cell lung carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Completed | hepatocellular carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Active, not recruiting | head and neck squamous cell carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Completed | diffuse large B-cell lymphoma | ClinicalTrials ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Active, not recruiting | neoplasm | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Active, not recruiting | non-small cell lung carcinoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Completed | non-Hodgkins lymphoma | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Active, not recruiting | urinary bladder cancer | ClinicalTrials |
STAT3 | DANVATIRSEN | STAT-3 mRNA 3'UTR antisense inhibitor | 1 | Completed | cancer | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACSTAT3-Ser727 | |
---|---|
Cancer | Intensity |
BRCA | 1.74 |
COAD | |
HGSC | |
ccRCC | |
GBM | -1.099 |
HNSC | |
LUAD | -0.272 |
LUSC | |
non_ccRCC | -0.473 |
PDAC | 0.531 |
UCEC | -0.428 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 727 | D | Oral squamous epithelial carcinoma | Phosphorylation | 23733313 |
S | 727 | D | Triple-negative breast cancer | Phosphorylation | 36017196 |
S | 727 | D | Pancreatic cancer | Phosphorylation | 37548811 |
S | 727 | D | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 18519681 |
S | 727 | P | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 23941877 |
S | 727 | P | Breast cancer/tumor/carcinoma | Phosphorylation | 23329648 ;  23329839 |
S | 727 | P | Cancer | Phosphorylation | 23145121 |
S | 727 | P | Melanoma | Phosphorylation | 22418867 |
S | 727 | U | Chronic lymphocytic leukemia | Phosphorylation | 35595309 |
S | 727 | U | Clear cell kidney cancer | Phosphorylation | 24615012 ;  33772065 ;  37945711 |
S | 727 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
S | 727 | U | Prostate cancer | Phosphorylation | 18829527 |
S | 727 | U | Glioblastoma multiforme | Phosphorylation | 35670018 |
S | 727 | U | B-cell acute lymphoblastic leukemia | Phosphorylation | 33393494 |
S | 727 | U | Hepatocellular carcinoma | Phosphorylation | 31498440 |
S | 727 | U | Thyroid cancer/carcinoma | Phosphorylation | 17209045 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P40763 | STAT3 | P | Ser727 | FICVTPTTCSNTIDLPMS(ph)PR | MDA-MB-175 | Pertuzumab | -4.9774 | - | |
P40763 | STAT3 | P | Ser727 | FICVTPTTCSNTIDLPMS(ph)PR | MDA-MB-175 | Trastuzumab | 1.4554 | - | |
P40763 | STAT3 | P | Ser727 | TKFICVTPTTCSNTIDLPMS(ph)PR | MDA-MB-175 | Trastuzumab | -0.3231 | - | |
P40763 | STAT3 | P | Ser727 | TKFICVTPTTCSNTIDLPMS(ph)PR | SK-BR-3 | Lapatinib | 7.1426 | - | |
P40763 | STAT3 | P | Ser727 | FICVTPTTCSNTIDLPMS(ph)PR | SK-BR-3 | Lapatinib | 6.1655 | - | |
P40763 | STAT3 | P | Ser727 | FICVTPTTCSNTIDLPMS(ph)PR | SK-BR-3 | Pertuzumab | -1.7721 | - | |
P40763 | STAT3 | P | Ser727 | FICVTPTTCSNTIDLPMS(ph)PR | SK-BR-3 | Trastuzumab | 0.8214 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.